VHL and cancer: The dependence on E3 ligase subunits can also lead to cancer cell resistance following chronic PROTAC treatment, as demonstrated in a study by Zhang et al., where cancer cells acquired resistance to both VHL-based and CRBN-based BET PROTACs [77,78].